Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01541033 · ClinicalTrials.gov registry record
Biomarker of Children With Familial Autoimmune History
A clinical trial, sponsored by Le Bonheur Children's Hospital.
- Completed
- Registry status
- 58
- Enrollment target
NCT01541033: Completed study, sponsored by Le Bonheur Children's Hospital.
NCT01541033 is a clinical trial that has completed, run by Le Bonheur Children's Hospital. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01541033 has completed, sponsored by Le Bonheur Children's Hospital.
- COMPLETED
- Registry status
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to identify biomarkers in this subset of autism patients, design a protein based assay system for screening serum for these biomarkers and confirm that these serum antibodies are still present at one year's time.
Primary Outcome
The designed techniques will be used to first identify and then determine the frequency of autoimmune markers cross reacting with fly neuronal proteins in children with carefully characterized autism with and without a positive familial autoimmune history (FAH) in a first degree relative compared to typically developing children without FAH.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2009-11 |
| Est. Completion | 2016-08 |
What the finished NCT01541033 record still lists
NCT01541033 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 58 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01541033 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01541033 about?
NCT01541033 is a clinical study titled "Biomarker of Children With Familial Autoimmune History". The purpose of this study is to identify biomarkers in this subset of autism patients, design a protein based assay system for screening serum for these biomarkers and confirm that these serum antibodies are still present at one year's time.
What is the current status of trial NCT01541033?
This trial is currently completed. The enrollment target is 58 participants. The study started on 2009-11. Estimated completion is 2016-08.
Who is sponsoring clinical trial NCT01541033?
This trial is sponsored by Le Bonheur Children's Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia